rBPI21 (opebacan) promotes rapid trilineage hematopoietic recovery in a murine model of high-dose total body irradiation

Kenneth J. Janec, Huaiping Yuan, James E. Norton, Rowan H. Kelner, Christian K. Hirt, Rebecca Betensky, Eva C. Guinan

Research output: Contribution to journalArticle

Abstract

The complexity of providing adequate care after radiation exposure has drawn increasing attention. While most therapeutic development has focused on improving survival at lethal radiation doses, acute hematopoietic syndrome (AHS) occurs at substantially lower exposures. Thus, it is likely that a large proportion of such a radiation-exposed population will manifest AHS of variable degree and that the medical and socioeconomic costs of AHS will accrue. Here, we examined the potential of rBPI21 (opebacan), used without supportive care, to accelerate hematopoietic recovery after radiation where expected survival was substantial (42%-75%) at 30 days. rBPI21 administration was associated with accelerated recovery of hematopoietic precursors and normal marrow cellularity, with increases in megakaryocyte numbers particularly marked. This translated into attaining normal trilineage peripheral blood counts 2-3 weeks earlier than controls. Elevations of hematopoietic growth factors observed in plasma and the marrow microenvironment suggest the mechanism is likely multifactorial and not confined to known endotoxin-neutralizing and cytokine downmodulating activities of rBPI21. These observations deserve further exploration in radiation models and other settings where inadequate hematopoiesis is a prominent feature. These experiments also model the potential of therapeutics to limit the allocation of scarce resources after catastrophic exposures as an endpoint independent of lethality mitigation.

Original languageEnglish (US)
Pages (from-to)1002-1013
Number of pages12
JournalAmerican Journal of Hematology
Volume93
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Whole-Body Irradiation
Radiation
Bone Marrow
Megakaryocytes
Resource Allocation
Hematopoiesis
Endotoxins
Intercellular Signaling Peptides and Proteins
Cytokines
Costs and Cost Analysis
Therapeutics
Population

ASJC Scopus subject areas

  • Hematology

Cite this

rBPI21 (opebacan) promotes rapid trilineage hematopoietic recovery in a murine model of high-dose total body irradiation. / Janec, Kenneth J.; Yuan, Huaiping; Norton, James E.; Kelner, Rowan H.; Hirt, Christian K.; Betensky, Rebecca; Guinan, Eva C.

In: American Journal of Hematology, Vol. 93, No. 8, 01.08.2018, p. 1002-1013.

Research output: Contribution to journalArticle

Janec, Kenneth J. ; Yuan, Huaiping ; Norton, James E. ; Kelner, Rowan H. ; Hirt, Christian K. ; Betensky, Rebecca ; Guinan, Eva C. / rBPI21 (opebacan) promotes rapid trilineage hematopoietic recovery in a murine model of high-dose total body irradiation. In: American Journal of Hematology. 2018 ; Vol. 93, No. 8. pp. 1002-1013.
@article{ab1ba60d807d4b28bd2f3a5609701ade,
title = "rBPI21 (opebacan) promotes rapid trilineage hematopoietic recovery in a murine model of high-dose total body irradiation",
abstract = "The complexity of providing adequate care after radiation exposure has drawn increasing attention. While most therapeutic development has focused on improving survival at lethal radiation doses, acute hematopoietic syndrome (AHS) occurs at substantially lower exposures. Thus, it is likely that a large proportion of such a radiation-exposed population will manifest AHS of variable degree and that the medical and socioeconomic costs of AHS will accrue. Here, we examined the potential of rBPI21 (opebacan), used without supportive care, to accelerate hematopoietic recovery after radiation where expected survival was substantial (42{\%}-75{\%}) at 30 days. rBPI21 administration was associated with accelerated recovery of hematopoietic precursors and normal marrow cellularity, with increases in megakaryocyte numbers particularly marked. This translated into attaining normal trilineage peripheral blood counts 2-3 weeks earlier than controls. Elevations of hematopoietic growth factors observed in plasma and the marrow microenvironment suggest the mechanism is likely multifactorial and not confined to known endotoxin-neutralizing and cytokine downmodulating activities of rBPI21. These observations deserve further exploration in radiation models and other settings where inadequate hematopoiesis is a prominent feature. These experiments also model the potential of therapeutics to limit the allocation of scarce resources after catastrophic exposures as an endpoint independent of lethality mitigation.",
author = "Janec, {Kenneth J.} and Huaiping Yuan and Norton, {James E.} and Kelner, {Rowan H.} and Hirt, {Christian K.} and Rebecca Betensky and Guinan, {Eva C.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1002/ajh.25136",
language = "English (US)",
volume = "93",
pages = "1002--1013",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - rBPI21 (opebacan) promotes rapid trilineage hematopoietic recovery in a murine model of high-dose total body irradiation

AU - Janec, Kenneth J.

AU - Yuan, Huaiping

AU - Norton, James E.

AU - Kelner, Rowan H.

AU - Hirt, Christian K.

AU - Betensky, Rebecca

AU - Guinan, Eva C.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - The complexity of providing adequate care after radiation exposure has drawn increasing attention. While most therapeutic development has focused on improving survival at lethal radiation doses, acute hematopoietic syndrome (AHS) occurs at substantially lower exposures. Thus, it is likely that a large proportion of such a radiation-exposed population will manifest AHS of variable degree and that the medical and socioeconomic costs of AHS will accrue. Here, we examined the potential of rBPI21 (opebacan), used without supportive care, to accelerate hematopoietic recovery after radiation where expected survival was substantial (42%-75%) at 30 days. rBPI21 administration was associated with accelerated recovery of hematopoietic precursors and normal marrow cellularity, with increases in megakaryocyte numbers particularly marked. This translated into attaining normal trilineage peripheral blood counts 2-3 weeks earlier than controls. Elevations of hematopoietic growth factors observed in plasma and the marrow microenvironment suggest the mechanism is likely multifactorial and not confined to known endotoxin-neutralizing and cytokine downmodulating activities of rBPI21. These observations deserve further exploration in radiation models and other settings where inadequate hematopoiesis is a prominent feature. These experiments also model the potential of therapeutics to limit the allocation of scarce resources after catastrophic exposures as an endpoint independent of lethality mitigation.

AB - The complexity of providing adequate care after radiation exposure has drawn increasing attention. While most therapeutic development has focused on improving survival at lethal radiation doses, acute hematopoietic syndrome (AHS) occurs at substantially lower exposures. Thus, it is likely that a large proportion of such a radiation-exposed population will manifest AHS of variable degree and that the medical and socioeconomic costs of AHS will accrue. Here, we examined the potential of rBPI21 (opebacan), used without supportive care, to accelerate hematopoietic recovery after radiation where expected survival was substantial (42%-75%) at 30 days. rBPI21 administration was associated with accelerated recovery of hematopoietic precursors and normal marrow cellularity, with increases in megakaryocyte numbers particularly marked. This translated into attaining normal trilineage peripheral blood counts 2-3 weeks earlier than controls. Elevations of hematopoietic growth factors observed in plasma and the marrow microenvironment suggest the mechanism is likely multifactorial and not confined to known endotoxin-neutralizing and cytokine downmodulating activities of rBPI21. These observations deserve further exploration in radiation models and other settings where inadequate hematopoiesis is a prominent feature. These experiments also model the potential of therapeutics to limit the allocation of scarce resources after catastrophic exposures as an endpoint independent of lethality mitigation.

UR - http://www.scopus.com/inward/record.url?scp=85051730942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051730942&partnerID=8YFLogxK

U2 - 10.1002/ajh.25136

DO - 10.1002/ajh.25136

M3 - Article

VL - 93

SP - 1002

EP - 1013

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 8

ER -